53,333 Shares in Moderna, Inc. $MRNA Acquired by Campbell & CO Investment Adviser LLC

Campbell & CO Investment Adviser LLC purchased a new stake in Moderna, Inc. (NASDAQ:MRNA) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 53,333 shares of the company’s stock, valued at approximately $1,471,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. SHANDA ASSET MANAGEMENT HOLDINGS Ltd bought a new position in shares of Moderna in the first quarter valued at about $28,350,000. Jacobs Levy Equity Management Inc. bought a new stake in shares of Moderna during the 1st quarter worth about $28,308,000. Jump Financial LLC grew its stake in Moderna by 5,590.0% in the 1st quarter. Jump Financial LLC now owns 902,427 shares of the company’s stock valued at $25,584,000 after buying an additional 886,567 shares during the last quarter. Invesco Ltd. raised its holdings in Moderna by 17.5% in the 1st quarter. Invesco Ltd. now owns 5,883,624 shares of the company’s stock valued at $166,801,000 after acquiring an additional 877,162 shares during the period. Finally, Sessa Capital IM L.P. acquired a new stake in Moderna during the first quarter worth approximately $21,066,000. 75.33% of the stock is owned by institutional investors.

Moderna Stock Performance

Shares of NASDAQ MRNA opened at $26.41 on Wednesday. The stock has a market capitalization of $10.32 billion, a P/E ratio of -3.27 and a beta of 2.02. The stock’s fifty day moving average is $25.86 and its 200 day moving average is $27.11. Moderna, Inc. has a 52 week low of $23.04 and a 52 week high of $48.92.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.15) by $1.64. Moderna had a negative net margin of 139.61% and a negative return on equity of 29.81%. The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $893.29 million. During the same period in the prior year, the company posted $0.03 earnings per share. The business’s revenue for the quarter was down 45.4% on a year-over-year basis. Moderna has set its FY 2025 guidance at EPS. Equities research analysts forecast that Moderna, Inc. will post -9.61 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Bank of America decreased their target price on Moderna from $24.00 to $21.00 and set an “underperform” rating on the stock in a research report on Monday. Evercore ISI set a $32.00 price objective on Moderna in a report on Friday, August 1st. UBS Group lowered their price objective on Moderna from $70.00 to $40.00 and set a “buy” rating on the stock in a research report on Thursday, October 23rd. Leerink Partners reduced their target price on shares of Moderna from $18.00 to $15.00 and set an “underperform” rating for the company in a research report on Friday, August 22nd. Finally, JPMorgan Chase & Co. decreased their price target on shares of Moderna from $26.00 to $25.00 and set an “underweight” rating on the stock in a research note on Thursday, October 23rd. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, twelve have issued a Hold rating and five have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $36.14.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.